11/14
11:31 am
gild
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet [Yahoo! Finance]
Low
Report
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet [Yahoo! Finance]
11/14
07:35 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $125.00 price target on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $125.00 price target on the stock.
11/13
08:24 pm
gild
Gilead Prices $3.5 Billion of Senior Unsecured Notes
Low
Report
Gilead Prices $3.5 Billion of Senior Unsecured Notes
11/13
02:06 pm
gild
Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear [Yahoo! Finance]
Low
Report
Gilead Sciences' (NASDAQ:GILD) Soft Earnings Are Actually Better Than They Appear [Yahoo! Finance]
11/13
06:45 am
gild
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Low
Report
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
11/13
12:12 am
gild
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight [Yahoo! Finance]
Low
Report
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight [Yahoo! Finance]
11/12
01:04 pm
gild
GILD or VRTX: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Low
Report
GILD or VRTX: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
11/12
05:30 am
gild
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
Medium
Report
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
11/10
09:37 am
gild
3 Spectacular High-Yield Dividend Stocks to Buy in November [Yahoo! Finance]
Low
Report
3 Spectacular High-Yield Dividend Stocks to Buy in November [Yahoo! Finance]
11/8
04:05 pm
gild
Gilead Sciences to Present at Upcoming Investor Engagements
Low
Report
Gilead Sciences to Present at Upcoming Investor Engagements
11/8
09:56 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Truist Financial Co. from $83.00 to $97.00. They now have a "hold" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Truist Financial Co. from $83.00 to $97.00. They now have a "hold" rating on the stock.
11/8
08:51 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating.
11/8
08:19 am
gild
Gilead Sciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Low
Report
Gilead Sciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
11/7
04:12 pm
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $95.00 to $105.00. They now have an "outperform" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $95.00 to $105.00. They now have an "outperform" rating on the stock.
11/7
01:58 pm
gild
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook [Yahoo! Finance]
Low
Report
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook [Yahoo! Finance]
11/7
01:41 pm
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $100.00 to $105.00. They now have an "overweight" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at JPMorgan Chase & Co. from $100.00 to $105.00. They now have an "overweight" rating on the stock.
11/7
01:41 pm
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Robert W. Baird from $80.00 to $95.00. They now have a "neutral" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Robert W. Baird from $80.00 to $95.00. They now have a "neutral" rating on the stock.
11/7
01:41 pm
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at BMO Capital Markets from $94.00 to $102.00. They now have an "outperform" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at BMO Capital Markets from $94.00 to $102.00. They now have an "outperform" rating on the stock.
11/7
12:59 pm
gild
Gilead increases 2024 outlook, expects new drug filing by end of year [Yahoo! Finance Canada]
Low
Report
Gilead increases 2024 outlook, expects new drug filing by end of year [Yahoo! Finance Canada]
11/7
12:35 pm
gild
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook [Yahoo! Finance]
Low
Report
Gilead Beats on Q3 Earnings and Sales, Raises Annual Outlook [Yahoo! Finance]
11/7
12:32 pm
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Royal Bank of Canada from $75.00 to $81.00. They now have a "sector perform" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Royal Bank of Canada from $75.00 to $81.00. They now have a "sector perform" rating on the stock.
11/7
12:32 pm
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $74.00 to $84.00. They now have a "neutral" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $74.00 to $84.00. They now have a "neutral" rating on the stock.
11/7
10:39 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Barclays PLC from $84.00 to $95.00. They now have an "equal weight" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Barclays PLC from $84.00 to $95.00. They now have an "equal weight" rating on the stock.
11/7
10:39 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Wells Fargo & Company from $100.00 to $105.00. They now have an "overweight" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Wells Fargo & Company from $100.00 to $105.00. They now have an "overweight" rating on the stock.
11/7
10:39 am
gild
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Cantor Fitzgerald from $70.00 to $80.00. They now have a "neutral" rating on the stock.
Low
Report
Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Cantor Fitzgerald from $70.00 to $80.00. They now have a "neutral" rating on the stock.